The Oral Endocrine Pivot: Inside Sling Therapeutics' $123M Bet on Linsitinib
DDDr. Dereck Mush, MD, MBA
Sep 18
Sling Therapeutics
Developing an oral small-molecule treatment for thyroid eye disease in a Phase 3 trial.
What they do
Sling Therapeutics is developing linsitinib, an investigational oral IGF-1R inhibitor for thyroid eye disease. Its Phase 3 ORBIT trial is evaluating the medicine in adults with active, moderate-to-severe disease following a $123 million Series C.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Thyroid eye disease
- Product type
- Service
- Stage
- Series C
- Headquarters
- Ann Arbor, United States
- Region
- North America
- Founded
- 2022
- Total funding
- $200M raised
Notable investors: Forbion, TPG Life Sciences Innovations, Sectoral Asset Management.
Also in Pharma & Drug Discovery
Related on The Signal
The Digital Therapeutics Evidence Gap: What FDA Authorization Actually Required
DDDr. Dereck Mush, MD, MBA
May 15
CAR-T therapy moves beyond cancer, and autoimmune disease becomes the next proving ground
DDDr. Dereck Mush, MD, MBA
Feb 4
A CDMO partnership shows how gene therapy manufacturing is scaling for chronic disease
DDDr. Dereck Mush, MD, MBA
Sep 3